Zerlasiran
Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer[1].
Product Specifications
CAS Number
2646703-64-0
Product Name Alternative
SLN360
UNSPSC
12352208
Target
Apolipoprotein; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/zerlasiran.html
Solubility
10 mM in DMSO
Smiles
[Zerlasiran]
Molecular Formula
C443H594F12N144O277P40S10
Molecular Weight
14155.81
References & Citations
[1]Rider DA, Eisermann M, Löffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240-247. |[2]Nissen SE, Wolski K, Watts GF, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein (a) : A Randomized Clinical Trial. JAMA. 2024;331 (18) :1534-1543.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15183858 1 Vial
Lentiviral mouse Edc3 shRNA (UAS) - Lentiviral mouse Edc3 shRNA (UAS) (100)
Sign In for Pricing
View Details 
![Rat Anti-Mouse/Human CD11b mAb (EV450) [M1/70]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)